Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial

Autor: Zhendong Chen, Zishu Wang, Helong Zhang, Ping Yang, Shanzhi Gu, Feng Chen, Zhenyu You, Bo Zhu, Yinying Lu, Feng Bi, Zhenggang Ren, Xi Chen, Zhendong Zheng, Xiaoli Xin, Junhui Chen, Aibing Xu, Jieer Ying, Xiaoyu Wen, Chengxu Cui, Liqing Wu, Jinlu Shan, Yuxian Bai, Hongming Pan, Jufeng Wang, Jian Wu, Li Xu, Zhiqiang Meng, Meng Qiu, Xiufeng Liu, Shukui Qin

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 39(27)

PURPOSE Donafenib, a novel multikinase inhibitor and a deuterated sorafenib derivative, has shown efficacy in phase Ia and Ib hepatocellular carcinoma (HCC) studies. This study compared the efficacy and safety of donafenib versus sorafenib as first-l

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90c01a79943a8d4f46b413cb0947c9c7
https://pubmed.ncbi.nlm.nih.gov/34185551

On Two-stage Seamless Adaptive Design in Clinical Trials

Autor: Shein-Chung Chow, Yi-Hsuan Tu

Publikováno v: Journal of the Formosan Medical Association, Vol 107, Iss 12, Pp S52-S60 (2008)

In recent years, the use of adaptive design methods in clinical research and development based on accrued data has become very popular because of its efficiency and flexibility in modifying trial and/or statistical procedures of ongoing clinical tria

Externí odkaz: https://doaj.org/article/9576d65b5f7d45deb160ed054d548d5b

GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II/III randomised controlled trial

Autor: Oughton, JB, Collett, L, Howard, DR, Hockaday, A, Munir, T, McMahon, K, McParland, L, Dimbleby, C, Phillips, D, Rawstron, AC, Hillmen, P

Publikováno v: Trials, Vol 18, Iss 1, Pp 1-12 (2017)
Trials
Oughton, JB, Collett, L, Howard, D R, Hockaday, A, Munir, T, McMahon, K, McParland, L, Dimbleby, C, Phillips, D, Rawstron, A C & Hillmen, P 2017, ' GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial : study protocol for a phase II/III randomised controlled trial. ', Trials, vol. 18, 353 . https://doi.org/10.1186/s13063-017-2107-0

Background Chronic lymphocytic leukaemia (CLL) is the most common adult leukaemia. Achieving minimal residual disease (MRD) negativity in CLL is an independent predictor of survival even with a variety of different treatment approaches and regardless

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::4a73a1c7b88eff553de89bf4b9f00509
http://link.springer.com/article/10.1186/s13063-017-2107-0